CD63 and breast carcinoma: The analysis conducted by two independent certified pathologists indicated a high degree of ITGAV‐CD63 colocalization in 37 out of 54 patients (68.5%) with locally advanced and metastatic breast cancer but only 18 out of 66 patients (27.3%) with early‐stage breast cancer indicating a significant difference between the two groups (χ2 = 20.4, P < 0.00001) (Figure 4h‐i).